Medhanie
Medhanie
Stop FollowingMedhanie
View as an RSS Feed
- Amarin's Descent To $5
- Groupon: Growth Vs. Profitability
- Gold: Why Bill Gross Is Wrong
- Arena Wins!
- Amarin: Short Now, Long Later
-
In Defense Of Groupon's Andrew Mason
- Complete Genomics: Say No To The Sale - Part 2
- Complete Genomics: Say No To Sale
- Despite Challenges, Obagi Is Still A Buy
- Arena: Bears Have It All Wrong
- Complete Genomics May Be Worth The Gamble
- Who Is Mad At Amarin?
- Amarin Must Be Acquired - And There Are Plenty of Potential Suitors
